Literature DB >> 8040117

The activity of 2-substituted quinoline alkaloids in BALB/c mice infected with Leishmania donovani.

A Fournet1, J C Gantier, A Gautheret, L Leysalles, M H Munos, J Mayrargue, H Moskowitz, A Cavé, R Hocquemiller.   

Abstract

Potent antileishmanial activity has recently been described in vivo when certain 2-substituted quinoline alkaloids are administered to mice with cutaneous leishmaniasis. We now report the antileishmanial activity of four 2-substituted quinoline alkaloids, namely chimanine D or 2-(1',2'-trans-epoxypropyl) quinoline (I), 2-n-propylquinoline (II), 2-styrylquinoline (III) and 2-(2'-hydroxypropyl) quinoline (IV), for experimental treatment of visceral leishmaniasis in infected BALB/c mice. Subcutaneous treatment with chimanine D for 10 days at 0.54 mmol/kg per day resulted in 86.6% parasite suppression in the liver. Oral administration of 0.54 mmol/kg of 2-n-propylquinoline once daily for 5 or 10 days to L. donovani-infected mice suppressed parasite burdens in liver by 87.8 and 99.9%, respectively. Cutaneous administration of meglumine antimonate for 10 days resulted in 97.4% parasite suppression in the liver. This study is, to our knowledge, the first to demonstrate the activity of 2-substituted quinoline alkaloids in experimental treatment of visceral leishmaniasis. Further biological and chemical studies of these products might yet prove helpful for the development of new antileishmanial drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8040117     DOI: 10.1093/jac/33.3.537

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases.

Authors:  Hector Nakayama; Philippe M Loiseau; Christian Bories; Susana Torres de Ortiz; Alicia Schinini; Elsa Serna; Antonieta Rojas de Arias; Mohamed A Fakhfakh; Xavier Franck; Bruno Figadère; Reynald Hocquemiller; Alain Fournet
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

3.  Investigational drugs for visceral leishmaniasis.

Authors:  Shyam Sundar; Jaya Chakravarty
Journal:  Expert Opin Investig Drugs       Date:  2014-11-20       Impact factor: 6.206

4.  In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis.

Authors:  A Fournet; M E Ferreira; A Rojas De Arias; S Torres De Ortiz; S Fuentes; H Nakayama; A Schinini; R Hocquemiller
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

5.  Successful Therapy of Murine Visceral Leishmaniasis with Astrakurkurone, a Triterpene Isolated from the Mushroom Astraeus hygrometricus, Involves the Induction of Protective Cell-Mediated Immunity and TLR9.

Authors:  Suvadip Mallick; Aritri Dutta; Ankur Chaudhuri; Debasri Mukherjee; Somaditya Dey; Subhadra Halder; Joydip Ghosh; Debarati Mukherjee; Sirin Salma Sultana; Gunjan Biswas; Tapan Kumar Lai; Pradyumna Patra; Indranil Sarkar; Sibani Chakraborty; Bhaskar Saha; Krishnendu Acharya; Chiranjib Pal
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

6.  Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system.

Authors:  Yaneth Osorio; Bruno L Travi; Adam R Renslo; Alex G Peniche; Peter C Melby
Journal:  PLoS Negl Trop Dis       Date:  2011-02-15

7.  Structures, targets and recent approaches in anti-leishmanial drug discovery and development.

Authors:  Karin Seifert
Journal:  Open Med Chem J       Date:  2011-03-09

Review 8.  The Role of Natural Products in Drug Discovery and Development against Neglected Tropical Diseases.

Authors:  Peter Mubanga Cheuka; Godfrey Mayoka; Peggoty Mutai; Kelly Chibale
Journal:  Molecules       Date:  2016-12-31       Impact factor: 4.411

Review 9.  GDP-Mannose Pyrophosphorylase: A Biologically Validated Target for Drug Development Against Leishmaniasis.

Authors:  Sébastien Pomel; Wei Mao; Tâp Ha-Duong; Christian Cavé; Philippe M Loiseau
Journal:  Front Cell Infect Microbiol       Date:  2019-05-31       Impact factor: 5.293

Review 10.  Alkaloids in Contemporary Drug Discovery to Meet Global Disease Needs.

Authors:  Sharna-Kay Daley; Geoffrey A Cordell
Journal:  Molecules       Date:  2021-06-22       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.